Associate Professor
Research Areas
Pharmacogenetics and Individualized Medication
Education and Practice System of Clinical Pharmacy
Education & Positions
Sichuan University (SU), B.S., 1981
Peking University Health Science Center (PUHSC), M.S., 1985
Peking University Health Science Center (PUHSC), Ph.D., 1991
Peking University Health Science Center (PUHSC), Assistant Professor, 1991-1997
Peking University Health Science Center (PUHSC), Associate Professor, 1997-
University of Kentucky, Visiting Scholar, 2007
Harvard Medical School / Boston Children’s Hospital, Visiting Associate Researcher, 2016-2017
Faculty Accolades
Excellent Mentor for Graduate Students, Peking University Health Science Center 2010-2011
Excellent Teacher in Educational Management, Peking UniversityHealth Science Center2011
Award of Teaching Achievements, Peking University Health Science Center 2008
Research Interests
Pharmacogenetics (Pharmacogenomics) may greatly improve the level of clinical medication, enhance the outcomes of clinical medication, increase the efficiency of diagnosis and therapeutics, and maintain and promote the quality of patients’ life in the true sense. Its research results can provide guideline for target drugs in new drug screening, and directly contribute theoretic basis and therapeutically practical policy on clinical rational medication, individualized medication and precision medicine. The individualized medication regimens based on our pharmacogenetic studies in past twenty years involve renal transplantation, epilepsy, depression, hypertensive and cardiovascular diseases, diabetes, cancers (breast cancer, ALL, NHL), myasthenia gravis and immunosuppressive therapies, peptic ulcer and chronic gastritis, antibiotic and antibacterial therapies, fracture surgical treatment, etc.
Grants and fundings
Genetics of nicotine addiction vulnerability (NIH). Co-PI
The relationship between genetic polymorphisms and drug metabolism phenotypes (Ministry of Science and Technology– Peking University Innovative Drug Platform). Participator
Clinical study on ethaselen – first class targeting new antitumor drug (Ministry of Science and Technology). PI
Publications
Zhou X, Wang X, Song Q, Yang H, Zhu X, Yu J, Song G, Di L, Ren J, Shao H*, Lyerly HK. Transformation of alkylating regimen of thiotepa into tepa determines the disease progression through GSTP1 gene polymorphism for metastatic breast cancer patients receiving thiotepa containing salvage chemotherapy. International Journal of Clinical Pharmacology and Therapeutics 2015; 53:914-922
Zhang YT, Yang LP, Shao H*, Li KX, Sun CH, Shi LW. ABCB1 polymorphisms may have minor effect on ciclosporin blood concentration in myasthenia gravis patients. British Journal of Clinical Pharmacology 2008; 66(2):240-246
Ryan M, Shao H*, Yang L, Nie XY, Zhai SD, Shi LW, Lubawy WC. Clinical pharmacy education in China. American Journal of Pharmaceutical Education 2008; 72(6):A129
Shao H, Song SJ and Clarke RC. Female-associated DNA polymorphisms of hemp (Cannabis sativa L.). Journal of Industrial Hemp. 8(1):5-9. 2003
Niu TH, Chen CZ, Ni JT, Wang BY, Fang Z, Shao H*, Xu XP. Nicotine dependence and its familial aggregation in Chinese. International Journal of Epidemiology 2000; 29:248-252